Pharmacological inhibition of TrxR1 and GSH depletion by jolkinolide B can augment ROS production, activating the MAPK pathway and priming cells for paraptosis in bladder cancer [39]. The gene discussed is TXNRD1; the disease is urinary bladder carcinoma.